Nyxoah SA (NYXH.BE) Stock Price, Financials & Summary

Key data

Open—

From 52W high—

Volume—

Market cap—

P/E (TTM)—

P/S (TTM)—

Div yield—

Key data

Open

—

From 52W high

—

Volume

—

Market cap

—

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

—

MomentumView details →

1D Return

—

YTD Return

—

SummaryUpdated Jun 1, 2026

Nyxoah S.A. (NASDAQ:NYXH) is a Belgian medical technology company founded in 2009 and headquartered in Mont-Saint-Guibert, Belgium. The company went public on NASDAQ in April 2021, focusing on developing innovative solutions for sleep-disordered breathing conditions. Nyxoah has established itself as a challenger in the hypoglossal nerve stimulation market, primarily competing against established players like Inspire Medical Systems. The company has achieved commercial success in Europe, particularly Germany, and is preparing for its U.S. market launch following anticipated FDA approval in early 2025.

Ask drillr about Nyxoah SA →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

—

YTD Return

—

1Y Return

—

RSI (14)

—

vs 50D SMA

—

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

22.65M

Net Income (TTM)

−98.48M

Op. CF (TTM)

−71.81M

Latest newsMore news →

Nyxoah announced the first patient implant in the BREATHE U.S. post-approval study of its Genio system, marking the start of the study's clinical rollout.13d ago

Nyxoah reported financial and operating results for the second quarter and first half of 2026, with U.S. net revenue of €5.2 million and global net revenue of €7.7 million for Q2 2026.46d ago

Latest newsMore news →

Nyxoah announced the first patient implant in the BREATHE U.S. post-approval study of its Genio system, marking the start of the study's clinical rollout.13d ago Nyxoah reported financial and operating results for the second quarter and first half of 2026, with U.S. net revenue of €5.2 million and global net revenue of €7.7 million for Q2 2026.46d ago